Q-VANT Biosciences develops and manufactures vaccine adjuvants to solve society priorities in prevention or eradication of diseases.
Q-VANT started to address and solved the QS-21 adjuvant supply security and quality obstacles for vaccine developers and manufacturers via a highly disruptive and proprietary technology platform.
Q-VANT changed the narrative on the availability of QS-21 by increasing the production capability to billion of doses and securing the supply in a 100% sustainable way.
